Home›Search›Lung Cancer: Targets and Therapy

Lung Cancer: Targets and Therapy

Dove Medical Press Ltd. · New Zealand · Est. 2010

ISSN1179-2728eISSN1179-2728

SJR Q2✓ WOS ESCI✓ Scopus / SJR✓ DOAJ✓ Open Access

Impact Factor & Quartile · Web of Science (JCR)

✓ Indexed in the Web of Science Core Collection (ESCI) — Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.

See the official Impact Factor & quartile on the journal’s page ↗

The Impact Factor & JCR quartile are licensed by Clarivate — we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q2. Source: Clarivate Journal Citation Reports.

📊 Standing in its field

Where this journal ranks among others in the same subject area.

SJR · Scopus

Top 50% in field

Clarivate’s JCR quartile is a separate ranking and may differ

SJR Scorei

1.028

H-Indexi

SNIPi

0.809

Total Worksi

212

Total Citationsi

3,687

2yr Mean Citednessi

2.28

Open Impact Factor alternative

Aims & Scope

An international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

General Information

Country / RegionNew Zealand

Primary LanguageEnglish

1st Year Published2010

FrequencyIrregular

StatusActive (last: 2026)

Total Publications212

Publisher OrgDove Medical Press

OA Since2009

Visit Journal Website

Submission Info

Peer ReviewSingle-blind

OA LicenseCC BY, CC BY-NC

OA Rate—

Ethics & Quality

COPE Member✗ No

OASPA Member✗ No

Not on Predatory Lists✓ Yes

Plagiarism Detection✓ Yes

Think.Check.Submit Compliance

thinkchecksubmit.org

9/11 · 82%

✅

Do you know the journal / publisher?

Dove Medical Press Ltd.

✅

Does the journal have a website?

✓ Linked

✅

Is the ISSN verified?

1179-2728 / 1179-2728

✅

Indexed in a trusted database?

WoS, Scopus, DOAJ, PubMed

✅

Peer review process documented?

Single-blind

❌

Follows ethical publishing standards (COPE)?

N/A

✅

Not on predatory/blacklists?

✓ Clean

❌

Long-term digital preservation?

N/A

✅

Plagiarism detection in place?

Yes

✅

Listed in DOAJ (verified OA)?

DOAJ verified

✅

Primary language documented?

English

A twelfth criterion — whether APC fees are clearly disclosed — is not scored here; it is left out of the total rather than counted as a failure. Publication charges appear in the metrics card above.

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published

Citations received

319

2019

168

2020

360

2021

2022

2023

2024

2025

2026

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

OncologyQ2

Subject Classification

Web of Science Categories

Oncology

Scopus Categories

Oncology

Research Topics (OpenAlex)

Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and TreatmentColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsCancer therapeutics and mechanismsHER2/EGFR in Cancer ResearchCancer-related Molecular PathwaysNeuroendocrine Tumor Research Advances

Frequently asked questions about Lung Cancer: Targets and Therapy

Is Lung Cancer: Targets and Therapy a predatory journal?

PubScope has no integrity flags on record for Lung Cancer: Targets and Therapy: it is indexed in Web of Science, Scopus, DOAJ, and is not on DOAJ's withdrawn list. Indexing is a transparency signal, not a guarantee — always confirm fit and policies before submitting.

What is the impact factor of Lung Cancer: Targets and Therapy?

Lung Cancer: Targets and Therapy is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal — including Arts & Humanities and Emerging Sources titles — receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. Its open 2-year mean citedness is 2.28.

Is Lung Cancer: Targets and Therapy indexed in Scopus and Web of Science?

Lung Cancer: Targets and Therapy is indexed in Web of Science, Scopus, DOAJ.